Hazim Bukamur1, Emhemmid Karem2, Serag Fares3, Saroj Sigdel4, Emad Alkhankan1, Fuad Zeid1. 1. Department of Pulmonary Medicine, Marshall University, Joan C. Edwards School of Medicine, Huntington, WV, 25701, USA. 2. Department of Internal Medicine, Marshall University, Joan C. Edwards School of Medicine, Huntington, WV, 25701, USA. 3. Allergy and Immunology Section, Internal Medicine Department, Rush University Medical Center, Chicago, IL, 60612, USA. 4. Department of Pathology Medicine, Marshall University, Joan C. Edwards School of Medicine, Huntington, WV, 25701, USA.
Abstract
Solitary fibrous tumors of the pleura (SFTPs) are rare neoplasms of mesenchymal origin most commonly arising in the pleura and have a benign biological behavior in the majority of cases. Most patients with SFTPs are asymptomatic; however, symptoms are mostly related to the mass effect within the thoracic cavity. Chest computed tomography (CT) scanning is the radiographic test of choice, but findings lack specificity. Surgical resection is the treatment of choice for most patients. Long-term survival after resection of benign SFTPs is excellent. In this case series, we present two females, one presented with shortness of breath (SOB) and nonproductive cough and the other one was referred because of abnormal x-ray findings. The histological as well as the immunohistochemical examination revealed the mass to be a solitary fibrous tumor of the pleura.
Solitary fibrous tumors of the pleura (SFTPs) are rare neoplasms of mesenchymal origin most commonly arising in the pleura and have a benign biological behavior in the majority of cases. Most patients with SFTPs are asymptomatic; however, symptoms are mostly related to the mass effect within the thoracic cavity. Chest computed tomography (CT) scanning is the radiographic test of choice, but findings lack specificity. Surgical resection is the treatment of choice for most patients. Long-term survival after resection of benign SFTPs is excellent. In this case series, we present two females, one presented with shortness of breath (SOB) and nonproductive cough and the other one was referred because of abnormal x-ray findings. The histological as well as the immunohistochemical examination revealed the mass to be a solitary fibrous tumor of the pleura.
Solitary fibrous tumor of the pleura (SFTP) is a rare, slowly growing tumor that originates from mesenchymal cells of the submesothelial tissue of the pleura [1,2], SFTPs can usually be distinguished from malignant mesothelioma by their radiographic features, gross appearance (often pedunculated), immunehistologic characteristics (negative for cytokeratin expression and positive for CD34), and ultrastructural characteristics [3].
Case number 1
A 57-year-old white female was referred from the outpatient clinic for abnormal chest x-ray, that showed 4.7 cm mass in the left upper lung lobe. The patient denied chest pain, cough, shortness of breath, and fever. A CT scan of chest without contrast showed smooth well-defined mass measures 3.5 × 4.4 × 2.8 cm in size at the anterior portion of the left first rib but there was no associated bone abnormality (Fig. 1, Fig. 2, Fig. 3). A positron emission tomography (PET) scan showed a 1.8 cm nodule at left upper lobe that is non-fluorodeoxyglucose (FDG) avid (Fig. 4). There was a no abnormal FDG uptake within the chest, abdomen, or pelvis.
Fig. 1
A CT scan of chest without contrast showed smooth well-defined mass measures 3.5 × 4.4 × 2.8 cm in size at the anterior portion of the left first rib.
Fig. 2
A coronal plane of the CT scan of chest showing a smooth well-defined mass at the anterior apical portion of the left lung.
Fig. 3
A sagittal plane of the CT scan of chest showing a smooth well-defined mass at the anterior apical portion of the left lung.
Fig. 4
A positron emission tomography (PET) scan showed a 1.8 cm nodule at left upper lobe that is non-fluorodeoxyglucose (FDG) avid.
A CT scan of chest without contrast showed smooth well-defined mass measures 3.5 × 4.4 × 2.8 cm in size at the anterior portion of the left first rib.A coronal plane of the CT scan of chest showing a smooth well-defined mass at the anterior apical portion of the left lung.A sagittal plane of the CT scan of chest showing a smooth well-defined mass at the anterior apical portion of the left lung.A positron emission tomography (PET) scan showed a 1.8 cm nodule at left upper lobe that is non-fluorodeoxyglucose (FDG) avid.The patient had a CT guided biopsy of the mass. The histopathogy examination revealed benign solitary fibrous tumor (Microscopic examination, low power view showed uniform cellular tumor with intralesional blood vessels (Fig. 5), higher power showed epithelioid cells and numerous angulated blood vessels (Fig. 6)). Tumor cells were positive immunohistochemical stain CD34 (Fig. 7), negative for cytokeratin AE1/AE3, high molecular weight cytokeratin, S100, desmin, and CD117 (Fig. 8), there was no evidence of increase in mitotic figures and no necrosis was noted. Based on this limited biopsy specimen. The patient underwent Video-assisted thoracoscopic surgery (VATS) with complete resection of left upper lobe mass. The patient followed up with serial CT scans of the chest for 2 years with no evidence of recurrence or new nodule.
Fig. 5
Low power view shows uniform cellular tumor with intralesional blood vessels.
Fig. 6
Higher power shows epithelioid cells and numerous angulated blood vessels.
Fig. 7
Tumor cells are positive immunohistochemical stain CD34.
Fig. 8
Tumor cells are negative for immunohistochemical stain cytokeratin AE1/AE3.
Low power view shows uniform cellular tumor with intralesional blood vessels.Higher power shows epithelioid cells and numerous angulated blood vessels.Tumor cells are positive immunohistochemical stain CD34.Tumor cells are negative for immunohistochemical stain cytokeratin AE1/AE3.
Case number 2
A 72-year-old white female was admitted to the hospital for progressive SOB and nonproductive cough. Laboratory workup revealed positive respiratory syncytial virus (RSV) rapid antigen. CT scan of the chest with IV contrast was negative for pulmonary embolism (PE) but showed 2 cm low-attenuation mass at the superior aspect of left major fissure (Fig. 9). Patient was treated for RSV tracheobronchitis and was discharged home. A follow-up CT chest 3 months later revealed the same finding. The patient underwent CT guided biopsy of the mass; PET scan showed a 1.9 cm nodule adjacent to the left major fissure that is non-FDG avid (Fig. 10). Tracer distribution was physiologic. No additional pulmonary nodule was noted.
Fig. 9
A CT scan of the chest showing a 2 cm low attenuation mass at the superior aspect of left major fissure.
Fig. 10
A positron emission tomography (PET) scan showed a 1.9 cm nodule adjacent to the left major fissure that is non-fluorodeoxyglucose (FDG) avid.
A CT scan of the chest showing a 2 cm low attenuation mass at the superior aspect of left major fissure.A positron emission tomography (PET) scan showed a 1.9 cm nodule adjacent to the left major fissure that is non-fluorodeoxyglucose (FDG) avid.Histopathology examination was consistent with benign solitary fibrous tumor (Microscopic examination, low power view showed cellular spindle cell neoplasm (Fig. 11), higher power showed monomorphic spindle cells (Fig. 12)). Immunohistochemical stains showed that tumor cells were strongly positive for CD34 (Fig. 13), negative for Cytokeratin AE1/AE3, high molecular weight cytokeratin, S100, desmin, and CD117 (Fig. 14).
Fig. 11
Low power view shows cellular spindle cell neoplasm.
Fig. 12
Higher power shows monomorphic spindle cells.
Fig. 13
Tumor cells are positive immunohistochemical stain CD34.
Fig. 14
Tumor cells are negative for immunohistochemical stain cytokeratin AE1/AE3.
Low power view shows cellular spindle cell neoplasm.Higher power shows monomorphic spindle cells.Tumor cells are positive immunohistochemical stain CD34.Tumor cells are negative for immunohistochemical stain cytokeratin AE1/AE3.The patient underwent left sided thoracotomy with wide wedge dissection of the upper lobe mass, and she did well since then. The patient is followed up with serial CT scans for 2 years. There was no recurrence or new nodule has found.
Discussion
SFTP is a rare neoplasm, with fewer than 800 cases reported in the literature [4]. The first report of a primary localized pleural tumor is attributed to Wagner in 1870 [5]. These tumors are frequently observed in middle-aged adults, greatest occurrence in the fourth to sixth decades, with no sex predilection [6]. There is no evidence of the relationship of such tumors with exposure to tobacco, asbestos, or any other environmental agents [7,8]. SFTs most commonly arises from pleura, with uncommon inward growth into lung parenchyma. Two-thirds of pleural SFTs occur in the visceral pleura and one-third occurs in the parietal pleura, where the tumors are often larger, with a broad-based attachment.The main differential diagnoses of SFT include pleural mesothelioma, peripheral bronchial carcinoma, solitary pleural metastasis, empyema, neurogenic sarcoma, synovial sarcoma, fibrosarcoma, and malignant fibrous histiocytoma [4,9]. The diagnostic approach to differentiate SFT from these conditions include history and physical, imaging include CXR, CT scan of the chest and PET scan, histopathologic and Immunohistochemistry as described below.Solitary fibrous tumors of the pleura can present with various clinical signs and symptoms such as dyspnea, chest pain, or hemoptysis. More rarely, paraneoplastic syndrome, presents as a hypoinsulinemic hypoglycemia (Doege–Potter syndrome), from the ectopic secretion of insulin-like growth factor II from a solitary fibrous tumor [10] and secondary hypertrophic osteoarthropathy (also known as, Bamberger-Marie syndrome or Osteoarthropathia hypertrophicans) [4]. It has been described in as many as 20% of the SFT cases, particularly in larger tumors (e.g. >7 cm) [11]. These paraneoplastic syndromes symptoms gradually disappear after tumor resection. Furthermore, SFTs can presents with non-specific symptoms such as fever, weight loss, and fatigue [12]. Although, approximately one-third of cases are found incidentally during chest imaging.Macroscopically, SFTs are usually large well circumscribed masses, with a fibrous pseudocapsule or serosal lining [13]. Pleural tumors are frequently associated with a pedicle; the pedicle typically contains large feeder vessels for the tumor. The cut surface of SFT ranges from firm and white for more fibrous tumors to a yellow-brown with homogenous density for cellular variants [13]. Hemorrhage, necrosis, and calcification can be seen [12], particularly in larger tumors.The majority of SFTs are benign and behave in a slow clinical course and very rarely to recur locally or distantly. However, malignant forms of SFT which forms a minority of SFTs are defined as hypercellular, nuclear pleomorphism mitotically active (>4 mitoses/10 high-power fields), tumor size >10 cm, and finding tumor necrosis, or stromal/vascular invasion [14,15].The diagnosis of SFT may be suspected based upon imaging and clinical features. However, a definitive diagnosis requires histologic confirmation. Complete resection is required for full histopathologic evaluation. Whereas fine needle aspiration biopsies are often inadequately cellular and are not recommended for diagnosis [16].On imaging pleural mesotheliomas are nearly always present as multiple pleural nodules or as a diffuse tumor that encases a portion of the lung. However, SFT typically appear in contact with the pleural surface and show displacement or invasion of the surrounding structures, and appear as homogeneous, well-delineated, and occasionally lobulated mass of soft tissue attenuation [4]. In some cases where SFT arises in an interlobar fissure makes it difficult to differentiate it from an intraparenchymal mass, as the lesion appears to be surrounded by lung parenchyma [4], as in our second case where the CT scan of the chest showed 2 cm low-attenuation mass at the superior aspect of left major fissure (Fig. 9).There is no definite imaging features to differentiate benign from malignant SFTP was found [8]. However, it can show the size and location of the tumor clearly and help in surgical planning. Large size, lobulate borders, presence of calcification, and ipsilateral pleural effusion were the only CT features predictive of malignancy.Neurogenic sarcoma, fibrosarcoma, Synovial sarcoma, and malignant fibrous histiocytoma can be misdiagnosed as SFT because of the dense, uniform spindle cell proliferation and the similar histologic patterns seen in these tumors. However, malignant SFT characterized by the presence of different patterns inside the same tumor and are not histologically uniform [4].Histologically, Benign fibrous pleural SFTs are hypocellular in character. It is characterized by a dense collagenous background, often with hyalinized or thick collagen bands and haphazard (lack of pattern) arrangement of monomorphic spindle cells with abundant ropy collagen mixed with tumor cells (18). Presence of hypercellular, pleomorphism, mitotic activity and necrosis may indicate aggressive behavior [17].Immunohistochemistry (IHC) is an extremely useful tool to differentiate SFT from other tumors (including mesotheliomas and other sarcomas). Conventional IHC markers of SFT include expression of CD34, Bcl2, CD99, and vimentin in the absence of actin, desmin, S100 protein, or epithelial markers (epithelial membrane antigen [EMA], low molecular weight cytokeratins) [18]. In our first case the microscopic examination showed cellular spindle cell lesion resembling fibroblasts, immunohistochemical stains was positive for CD34, negative for AE1/AE3, high molecular weight cytokeratin, S100, desmin, and CD117 consistent with the diagnosis of SFTP.Management of SFT should be discussed in a multidisciplinary tumor board with specialists who have experience with the disease. Surgical resection remains the mainstay of therapy for all localized SFTs [12]. The choice of surgical approach is affected by the size and location of tumors. There is no evidence that suggests that adjuvant chemotherapy is beneficial. By reviewing the literature, it was inconclusive with regards to the utility of postoperative radiotherapy (RT) for SFT treatment. Radiotherapy and chemotherapy have been used as adjuvant treatment when resection is incomplete or impossible. The median survival for patients with all types of SFT has been reported to be 24 years [8]. There is no clear evidence regarding the optimal interval of posttreatment surveillance, and no widely accepted guidelines. Careful long-term postoperative surveillance is recommended because local and distant relapse is possible, even with benign-appearing tumors. Our patients were followed for two years without recurrence.
Conclusion
In conclusion, SFT is a rare fibroblastic mesenchymal neoplasm that most likely arises from visceral pleura. Imaging can help in diagnoses, but definite diagnoses needs to be confirmed with histopathology, as well as immunohistochemistry. Surgical excision remains the mainstay of treatment. Long-term follow-up is recommended for early recurrence detection, particularly for tumors that have histological features for malignant behavior.
Data availability
All data are available in the manuscript.
Conflicts of interest
DR. Hazim Bukamur, DR. Emhemmid Karem, DR. Serag Fares, DR. Saroj Sigdel, DR. Emad Alkhankan, DR. Fuad Zeid have no conflict of interests to disclose related to the contents of the manuscript.
Funding statement
Not applicable.No funding was provided to any of the authors by any institution to write this case report and article review.
Authors' contributions
Hazim Bukamur, Emhemmid Karem, Serag Fares, Emad Alkhankan, participated in data collection and interpretation, and drafted the initial manuscript, Fuad Zeid critically revised the manuscript, Saroj Sigdel provided the slides and description of slides and revised the manuscript.
Consent for publication
Not applicable.No consent needed as this is a case report without any patient identifiers.
Ethics approval and consent to participate
Not applicable.No ethics approval nor consent is needed as this is a case report without any patient identifiers.
Authors: Hyun Jeong Kim; Ho Kyu Lee; Jeong Jin Seo; Hyung Jin Kim; Ji Hoon Shin; Ae Kyung Jeong; Jeong Hyun Lee; Kyung Ja Cho Journal: Korean J Radiol Date: 2005 Jul-Sep Impact factor: 3.500
Authors: Pierre Magdeleinat; Marco Alifano; Antonio Petino; Jean Philippe Le Rochais; Elisabeth Dulmet; Françoise Galateau; Philippe Icard; Jean François Regnard Journal: Eur J Cardiothorac Surg Date: 2002-06 Impact factor: 4.191
Authors: Karen M Harrison-Phipps; Francis C Nichols; Cathy D Schleck; Claude Deschamps; Stephen D Cassivi; Paul H Schipper; Mark S Allen; Dennis A Wigle; Peter C Pairolero Journal: J Thorac Cardiovasc Surg Date: 2009-07 Impact factor: 5.209
Authors: Valerio Perna; Francisco Rivas; Ricardo Morera; Josep Saumench; Ricard Ramos; Ivan Macia; Anna Ureña; Ignacio Escobar; Rosa Villalonga; Juan Moya Journal: Int J Surg Date: 2008-05-01 Impact factor: 6.071
Authors: Adrien Daigeler; Marcus Lehnhardt; Stefan Langer; Lars Steinstraesser; Hans-Ulrich Steinau; Thomas Mentzel; Cornelius Kuhnen Journal: BMC Surg Date: 2006-07-06 Impact factor: 2.102